Article Figures & Data
Figures
- FIGURE 1.
Progression-free survival curves according to initial lymph node status. There was no significant difference (P = 0.18) between pN0 and pNx patients. A significant difference was found between pN0 and pN1 (P = 0.0001) and between pNx and pN1 (P < 0.0001).
- FIGURE 2.
Progression-free survival curves according to Tg1 level measured in postoperative period just before IAT.
- FIGURE 3.
Progression-free survival curves according to Tg2 level measured 6–12 mo after IAT.
Tables
Characteristic No. of patients % Sex Male 59 28 Female 153 72 Age (y) <45 92 43 ≥45 120 57 Histologic subtype Papillary 184 87 Follicular 28 13 Tumor size (cm) ≤4 188 89 >4 24 11 Multifocality Absent 123 58 Present 89 42 Bilaterality Absent 149 70 Present 63 30 Extrathyroidal extension Absent 167 79 Present 45 21 Vascular invasion Absent 182 86 Present 30 14 Lymph node invasion pNx 93 44 pN0 63 30 pN1 56 26 - TABLE 2
Evolution of Thyroid Disease After Initial Therapy According to Tg1 and Tg2 Levels (ng/mL)
Evolution Tg1 ≤ 30 Tg1 > 30 Tg2 ≤ 10 Tg2 > 10 Tg2 ≤ 10 Tg2 > 10 Disease progression 4 3 1 12 Isolated elevated Tg 0 6 0 6 Complete remission 163 2 10 1 - TABLE 3
Univariate Analysis of Predictive Factors for Disease Progression 6–12 Months After IAT
Predictive factor OR 95% CI P value Tg2 > 10 ng/mL 22.6 8.2–62.5 <0.001 Tg1 > 30 ng/mL 12.5 5.0–31.5 <0.001 Node invasion 6.0 2.4–15.0 <0.001 Extrathyroidal extension 3.2 1.3–7.9 0.009 Tumor size > 4 cm 3.1 1.1–8.5 0.03 OR = odds ratio; 95% CI = 95% confidence interval.
- TABLE 6
Distribution of Clinical Events After 5-Year Follow-Up According to Tg1 Level and Lymph Node Status
Tg1 level and lymph node status No events Events N− and Tg1 ≤ 30 ng/mL 69 2 N+ or Tg1 > 30 ng/mL 24 14 N− = node invasion absent; N+ = node invasion present.
- TABLE 7
Distribution of Clinical Events After 5-Year Follow-Up According to Tg2 Level and Lymph Node Status
Tg2 level and lymph node status No events Events N− and Tg2 ≤ 10 ng/mL 72 2 N+ or Tg2 > 10 ng/mL 21 14 N− = node invasion absent; N+ = node invasion present.
In this issue
Jump to section
Related Articles
Cited By...
- Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden
- Low risk papillary thyroid cancer
- Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation
- Postablation 131I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer
- Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level
- Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study
- A new functional parameter measured at the time of ablation that can be used to predict differentiated thyroid cancer recurrence during follow-up
- Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report
- Is Empiric 131I Therapy Justified for Patients with Positive Thyroglobulin and Negative 131I Whole-Body Scanning Results?
- Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients